R
Roy L. Kisliuk
Researcher at Tufts University
Publications - 198
Citations - 4783
Roy L. Kisliuk is an academic researcher from Tufts University. The author has contributed to research in topics: Dihydrofolate reductase & Thymidylate synthase. The author has an hindex of 39, co-authored 198 publications receiving 4626 citations. Previous affiliations of Roy L. Kisliuk include Xavier University & Indiana University.
Papers
More filters
Journal ArticleDOI
Design and synthesis of classical and nonclassical 6-arylthio-2,4-diamino-5-ethylpyrrolo[2,3-d]pyrimidines as antifolates.
TL;DR: Nine classical analogues and 15 nonclassical analogues were synthesized as potential dihydrofolate reductase (DHFR) inhibitors and as antitumor agents and some were potent and selective inhibitors of DHFR from two pathogens that cause opportunistic infections in patients with compromised immune systems.
Journal ArticleDOI
Dihydrofolate reductase from Lactobacillus casei. X-ray structure of the enzyme methotrexate.NADPH complex.
D A Matthews,R A Alden,Jeffrey T. Bolin,David J. Filman,S T Freer,R Hamlin,W G Hol,Roy L. Kisliuk,Edward J. Pastore,Laurence T. Plante,Nguyen-Huu Xuong,Joseph Kraut +11 more
Journal ArticleDOI
Polyglutamyl derivatives of folate as substrates and inhibitors of thymidylate synthetase.
TL;DR: Inhibition obtained with diHydropteroylhexaglutamate and dihydropteroysltriglutamate is sufficient to warrant consideration of these compounds as physiological regulators of thymidylate formation.
Journal ArticleDOI
Properties of Thymidylate Synthetase from Dichloromethotrexate-resistant Lactobacillus casei
TL;DR: Extracts of dichloromethotrexate-resistant Lactobacillis casei provide a rich source of stable thymidylate synthetase, showing 100 times the activity found in extracts of the sensitive strain this paper.
Journal ArticleDOI
2,4-Diamino-5-deaza-6-substituted pyrido[2,3-d]pyrimidine antifolates as potent and selective nonclassical inhibitors of dihydrofolate reductases
TL;DR: Fifteen novel nonclassical and two classical 2,4-diamino-6-(benzylamino)pyrido[2,3-d]pyrimidine antifolates were synthesized as potential inhibitors of Pneumocystis carinii, Toxoplasma gondii, rat liver, and human (h) recombinant dihydrofolate reductases (DHFR).